US Patent
US11977067 — Abaloparatide formulations and methods of testing, storing, modifying, and using same
Formulation · Assigned to Radius Health Inc · Expires 2038-04-30 · 12y remaining
Vulnerability score
55/100
Moderate — design-around opportunities exist
What this patent protects
This patent protects methods of analyzing, storing, and using abaloparatide, specifically in relation to its isomers.
USPTO Abstract
Provided herein are newly discovered methods of analyzing abaloparatide samples for abaloparatide isomers. Additionally, methods of storing and treating with abaloparatide in view of the newly discovered abaloparatide isomers are described.
Drugs covered by this patent
- Tymlos (ABALOPARATIDE) · Radius
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.